

IFW

55.5		Occupated Strange				
Fees pursuant to HANF bidated Appropriations Act, 2005 (H.R.	Complete if Known           Application Number         10/528,806/Conf. #6218					
FEE TRANSMITTAL			June 14, 2005			
			Jan Menne			
For FY 2005	Examiner Name		To Be Assigned			
Applicant claims small entity status. See 37 CFR 1.27	Art Unit 1		1614			
TOTAL AMOUNT OF PAYMENT (\$) 0.00		Attorney Docket No. 3		37998-237159		
METHOD OF PAYMENT (check all that apply)						
Check Credit Card Money Order None Other (please identify):						
X Deposit Account Deposit Account Number: 22-0261 Deposit Account Name: Venable LLP						
For the above-identified deposit account, the Director is hereby authorized to: (check all that apply)						
Charge fee(s) indicated below Charge fee(s) indicated below, except for the filing fee						
Charge any additional fee(s) or underpayment of fee(s) under 37 CFR 1.16 and 1.17						
FEE CALCULATION						
1. BASIC FILING, SEARCH, AND EXAMINATION FEES						
FILING FEES	SE	ARCH FEES	EXAMINA	ATION FEES		
Application Type Fee (\$) Fee (\$)	Fee (\$	Small Entity ) Fee (\$)	Fee (\$)	Small Entity Fee (\$)	Fees P	aid (\$)
Utility 300 150	500	250	200	100		
Design 200 100	100	50	130	65		*
Plant 200 100	300	150	160	80		
Reissue 300 150	500	250	600	300		
Provisional 200 100	0	0	0	0		
2. EXCESS CLAIM FEES	ŭ	· ·	· ·	Ū		Small Entity
Fee Description Fee (\$)						
Each claim over 20 (including Reissues)				50	25	
Each independent claim over 3 (including Reissues)					200	100
Multiple dependent claims	n_:-! (e)	341	tinla Dananda	360	180	
Total Claims Extra Claims Fee (\$) Fee Paid (\$)			-	Multiple Dependent Claims Fee (\$) Fee Paid (\$)		
HP = highest number of total claims paid for, if greater than 20.				787 -		•
Indep. Claims Extra Claims Fee (\$)	ee (\$) Fee Paid (\$)					_
- 3 = x = HP = highest number of independent claims paid for, if greater than 3.						
3. APPLICATION SIZE FEE						
If the specification and drawings exceed 100 sheets of paper (excluding electronically filed sequence or computer listings under 37 CFR 1.52(e)), the application size fee due is \$250 (\$125 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).						
Total Sheets Extra Sheets Number of each additional 50 or fraction thereof Fee (\$) Fee Paid (\$)						
100 = /50 (round <b>up</b> to a whole number) x =						
4. OTHER FEE(S) Fees Paid (\$)						
Non-English Specification, \$130 fee (no small entity discount)						
Other (e.g., late filing surcharge):						
SUBMITTED BY						
Registration No. (Attorney/Agent) 36,203				Telephone (202) 344-4000		
Name (Print/1908) Steven R. Ludwig				Date October 5, 2006		



## Docket No. MENT TRANSMITTAL LETTER 37998-237159 Filing Date Examiner Art Unit Application No. 10/528,806/Conf. # 6218 June 14, 2005 To be assigned 1614 Applicant(s): MENNE et al. INHIBITION OF PROTEIN KINASE C ALPHA FOR THE TREATMENT OF Invention: CARDIOVASCULAR DISEASES TO THE COMMISSIONER FOR PATENTS Transmitted herewith is a preliminary amendment in the above-identified application. The fee has been calculated and is transmitted as shown below. **CLAIMS AS AMENDED** Claims Highest Remaining Number Number Previously **Extra Claims** After Amendment Paid Present 50.00 0.00 **Total Claims** 60 60 Х 0 Independent 1 3 = 0 200.00 0.00 **Claims** Multiple Dependent Claims (check if applicable) Other fee (please specify): TOTAL ADDITIONAL FEE FOR THIS AMENDMENT: 0.00 Large Entity x Small Entity x | No additional fee is required for this amendment. Please charge Deposit Account No. in the amount of \$ A duplicate copy of this sheet is enclosed. A check in the amount of \$ to cover the filing fee is enclosed. Payment by credit card. Form PTO-2038 is attached. 22-0261 X The Director is hereby authorized to charge and credit Deposit Account No. as described below. A duplicate copy of this sheet is enclosed. Credit any overpayment. Charge any additional filing or application processing fees required under 37 CFR 1.16 and 1.17. Dated: October 5, 2006 Steven R Ladwig Attorney/Agent Reg. No.:, 36,203 **VENABLE LLP** P.O. Box 34385 Washington, DC 20043-9998 (202) 344-4000



Docket No.: 37998/237159

(PATENT)

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

MENNE et al.

Art Unit: 1614

Application No: 10/528,806

Examiner: Not Yet Assigned

Confirmation No: 6218

Filed: June 14, 2005

Atty. Docket No: 37998/237159

Customer No:

For: INHIBITION OF PROTEIN KINASE C ALPHA FOR THE TREATMENT OF

CARDIOVASCULAR DISEASES (As

\*26694\*

26694

Amended)

PATENT TRADEMARK OFFICE

## THIRD PRELIMINARY AMENDMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

## INTRODUCTORY COMMENTS

Prior to examination on the merits, please amend the above-identified U.S. patent application as follows:

Amendments to the Specification begin on page 2 of this paper.

Amendments to the Claims are reflected in the listing of claims which begins on page 3 of this paper.

Remarks/Arguments begin on page 9 of this paper.